Abstract
Fixed-dose dextromethorphan/quinidine capsules (Nuedexta®) utilize quinidine to inhibit the metabolism of dextromethorphan, enabling high plasma dextromethorphan concentrations to be reached without using a larger dose of the drug. The drug combination is the first treatment to be approved for pseudobulbar affect (PBA), a condition of contextually inappropriate/exaggerated emotional expression that often occurs in adults with neurological damage conditions, such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), stroke, traumatic brain injury, Alzheimer’s disease or Parkinson’s disease. Dextromethorphan/quinidine at the recommended dosages of 20/10 or 30/10 mg twice daily reduced the rate of PBA episodes and improved PBA severity in a 12-week, double-blind, placebo-controlled trial in adults with ALS or MS (STAR), with further improvements in the severity of the condition observed in a 12-week open-label extension phase. Dextromethorphan/quinidine 20/10 mg twice daily also improved PBA secondary to dementia in a cohort of a 12-week noncomparative trial (PRISM II). The drug combination was generally well tolerated in these studies, with no particular safety or tolerability concerns. Although longer-term efficacy and tolerability data for dextromethorphan/quinidine 20/10 or 30/10 mg twice daily would be beneficial, current evidence indicates that it is a useful option in the treatment of adults with PBA.
Similar content being viewed by others
References
Parvizi J, Coburn KL, Shillcutt SD, et al. Neuroanatomy of pathological laughing and crying: a report of the American Neuropsychiatric Association Committee on Research. J Neuropsychiatry Clin Neurosci. 2009;21(1):75–87.
Miller A, Pratt H, Schiffer RB. Pseudobulbar affect: the spectrum of clinical presentations, etiologies and treatments. Expert Rev Neurother. 2011;11(7):1077–88.
Parvizi J, Arciniegas DB, Bernardini GL, et al. Diagnosis and management of pathological laughter and crying. Mayo Clin Proc. 2006;81(11):1482–6.
Werling LL, Keller A, Frank JG, et al. A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder. Exp Neurol. 2007;207(2):248–57.
Pioro EP. Current concepts in the pharmacotherapy of pseudobulbar affect. Drugs. 2011;71:1193–207.
Marier JF, Deschenes JL, Hage A, et al. Enhancing the uptake of dextromethorphan in the CNS of rats by concomitant administration of the P-gp inhibitor verapamil. Life Sci. 2005;77(23):2911–26.
European Medicines Agency. Nuedexta (dextromethorphan/quinidine) oral capsules: EU summary of product characteristics. http://www.ema.europa.eu. Accessed 5 Nov 2014.
Avanir Pharmaceuticals Inc. Nuedexta® (dextromethorphan hydrobromide and quinidine sulfate) oral capsules: US prescribing information. 2010. https://www.nuedexta.com. Accessed 5 Nov 2014.
Andersen PM, Abrahams S, Borasio GD, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS): revised report of an EFNS task force. Eur J Neurol. 2012;19(3):360–75.
Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73(15):1227–33.
Codd EE, Shank RP, Schupsky JJ, et al. Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther. 1995;274(3):1263–70.
Nguyen L, Robson MJ, Healy JR, et al. Involvement of sigma-1 receptors in the antidepressant-like effects of dextromethorphan. PLoS One. 2014;9(2):e89985.
Haiman G, Pratt H, Miller A. Effects of dextromethorphan/quinidine on auditory event-related potentials in multiple sclerosis patients with pseudobulbar affect. J Clin Psychopharmacol. 2009;29(5):444–52.
Brooks BR, Bravver E, Desai UG, et al. Bulbar speech-articulation/swallowing rate changes measured in amyotrophic lateral sclerosis (ALS) patients treated with dextromethorphan/quinidine(nuedexta) for pseudobulbar affect (PBA)-determination of treatment effect size for future clinical trials [abstract no. M1408]. Ann Neurol. 2012;72(S16):S65–6.
Zawertailo LA, Tyndale RF, Busto U, et al. Effect of metabolic blockade on the psychoactive effects of dextromethorphan. Hum Psychopharmacol. 2010;25(1):71–9.
European Medicines Agency. Neudexta (dextromethorphan/quinidine): assessment report for an initial marketing authorisation application. 25 Apr 2013. http://www.ema.europa.eu. Accessed 5 Nov 2014.
Pioro EP, Brooks BR, Cummings J, et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol. 2010;68(5):693–702.
Pope LE, Khalil MH, Berg JE, et al. Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers. J Clin Pharmacol. 2004;44(10):1132–42.
Capon DA, Bochner F, Kerry N, et al. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. Clin Pharmacol Ther. 1996;60(3):295–307.
Pope LE, Schoedel KA, Bartlett C, et al. A study of potential pharmacokinetic and pharmacodynamic interactions between dextromethorphan/quinidine and memantine in healthy volunteers. Clin Drug Investig. 2012;32(8):e1–15.
Pioro E, Brooks B, Cummings J, et al. Persistent efficacy of dextromethorphan (DM)/quinidine (Q) for pseudobulbar affect (PBA): results from a 12-week, open-label extension (OLE) study [abstract no. LBS.006]. Neurology. 2010;75(4):380.
Doody RS, D’Amico S, Cutler AJ, et al. Safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with Alzheimer’s disease/dementia: PRISM II [poster no. M1334WIP]. In: 139th Annual Meeting of the American Neurological Association, Baltimore (MD); 2014.
Avanir Pharmaceuticals. Safety and efficacy of AVP-923 in PBA patients with ALS or MS (STAR) [ClinicalTrial.gov identifier NCT00573443]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov. Accessed 5 Nov 2014.
Jillapalli D. US FDA center for drug evaluation and research: medical review of Zenvia. 25 Sep 2010. http://www.accessdata.fda.gov. Accessed 30 Aug 2013.
Pioro E, Brooks B, Cummings J, et al. Safety and tolerability of dextromethorphan/quinidine for pseudobulbar affect in a 12-week, open-label extension study [abstract no. P06.128]. In: 62nd Annual Meeting of the American Academy of Neurology, Toronto (ON); 2010.
Siffert J, Abijo O, Formella A. Dextromethorphan 20 mg/quinidine 10 mg effectiveness and tolerability in treating PBA in patients with stroke, dementia and other neurological conditions: results of a retrospective chart review [abstract]. Consult Pharm. 2013;28(10).
Cruz MP. Nuedexta for the treatment of pseudobulbar affect. Drug Forcast. 2013;38(6):325–8.
Pattee GL, Wymer JP, Lomen-Hoerth C, et al. An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions. Curr Med Res Opin. 2014;30(11):2255–65.
Cummings JL. Neuropsychiatric inventory: comprehensive assessment of psychopathology in patients with dementia. 2009. http://www.dementia-assessment.com.au/behavioural/index.html. Accessed 5 Nov 2014.
Disclosure
The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the authors on the basis of scientific and editorial merit. Lily Yang and Emma Deeks are salaried employees of Springer.
Author information
Authors and Affiliations
Corresponding author
Additional information
The manuscript was reviewed by: J. M. Silver, Department of Psychiatry, New York University School of Medicine; New York, NY, USA; L. Zawertailo, Centre for Addiction and Mental Health, Department of Pharmacology, University of Toronto, Toronto, Canada.
Rights and permissions
About this article
Cite this article
Yang, L.P.H., Deeks, E.D. Dextromethorphan/Quinidine: A Review of Its Use in Adults with Pseudobulbar Affect. Drugs 75, 83–90 (2015). https://doi.org/10.1007/s40265-014-0328-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-014-0328-z